用于治疗性结肠炎的热敏水凝的配方
Deepa Sathesh1, K Sathesh Kumar1, Velmurugan Devadasan2
1Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, India.
Bioinformation
|September 1, 2023
概括
来自海洋的富可伊丹和原被配制成一种用于治疗性结肠炎 (UC) 的水凝. 这种新的配方在小鼠模型中显著降低了炎症和症状,超过了现有的治疗方法.
科学领域:
- 海洋生物技术 海洋生物技术
- 胃肠病学 胃肠病学
- 药物输送系统是药物输送系统.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病 (IBD),治疗选择有限,影响20%-40%的患者.
- 传统的UC疗法,如类固醇和免疫抑制剂,具有感染和免疫抑制的风险.
- 海洋衍生化合物为UC管理提供潜在的抗炎替代品.
研究的目的:
- 调查福科伊丹和原作为UC的潜在抗炎药物.
- 开发一种持续释放的富可伊丹 - 原凝配方,用于增强UC治疗.
- 为了评估福可伊丹 - 原水凝在硫酸 (DSS) 诱导的大肠炎小鼠模型中的疗效.
主要方法:
- 从Turbinaria ornate中分离fucoidan,并从阿基里斯肌中制备原蛋白.
- 配制了一种富可伊丹-原蛋白水凝,表现出sol-gel过渡和持续释放12小时.
- 向DSS诱导的大肠炎小鼠给予富可伊丹,原蛋白和富可伊丹-原蛋白水凝,以评估疗效.
主要成果:
- 在大肠炎模型中,富可伊丹 - 原凝显著降低了临床得分和直肠出血.
- 水凝配方与单独的富可伊丹和原治疗相比,显示出更高的疗效.
- 富可伊丹-原凝的治疗效果超过了参考药物梅萨拉的治疗效果.
结论:
- 一种新型的富可伊丹 - 原凝有效治疗实验性性结肠炎.
- 这种来自海洋的水凝配方为UC提供了有前途的治疗策略.
- 富可伊丹和原的持续释放和协同作用有助于改善抗炎症结果.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
493
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
493
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Peptic Ulcer Disease IV: Management
110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
551
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
551
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152


